noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Orrick, Herrington & Sutcliffe LLP

Orrick advises the Finance Parties on the €1.29 billion refinancing of[...]
Illinois Department of Agriculture

GOVERNOR PRITZKER ANNOUNCES ATTENDANCE RESULTS FOR 2025 STATE FAIRS
United States Attorney's Office[...]

Ohio Man Sentenced to Prison for Robbing Postal Employee

Healthcare

Nuvalent Inc.

09/22/2025 | Press release | Distributed by Public on 09/23/2025 09:14

Material Event (Form 8-K)

Item 8.01. Other Events.

On September 22, 2025, Nuvalent, Inc. announced the completion of its New Drug Application submission to the U.S. Food and Drug Administration for zidesamtinib in tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer.

Nuvalent Inc. published this content on September 22, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 23, 2025 at 15:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]